Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Neurogene Inc. (NGNE)
USD39.32
+0.24 (+0.61%)
US NASDAQ Healthcare Biotechnology
Address
535 W 24th Street 10011
New York City, NY, US
New York City, NY, US
CEO
Rachel L. McMinn
Website
neurogene.com
IPO
2014-03-07
CIK 1404644 ISIN US64135M1053
Description
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD39.32
+0.24 (+0.61%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
183.0K
Beta
1.96
Float Shares
12.37M
Free Float %
79.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.42% | +7.06% | +69.19% | +87.69% | +23.14% | +58.35% | +110.32% | +88.55% | -84.30% | -75.14% | -86.35% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (6 ratings, all time)
Buy
Price Targets & DCF
Current price
39.32
Low
69.00
+75.5%
Consensus
69.00
+75.5%
Median
69.00
+75.5%
High
69.00
+75.5%
DCF (Unlevered)
4.36
-88.9%
DCF (Levered)
4.44
-88.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 9 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
69.00
+75.5%
|
| Last Quarter | 1 |
69.00
+75.5%
|
| Last Year | 2 |
57.00
+45.0%
|
| All Time | 13 |
49.85
+26.8%
|
Quality scores
Altman Z-Score
9.35
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+0.9% Q1'26: -28.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-1,790.3% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.5% Q1'26: +6.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.10× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2018 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 7 EPS Ana. |
Dec 2027 4 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 3 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
25.00M
est: 25.00M (+0.0%)
|
925.0K
est: 905.0K (+2.2%)
|
—
|
462.5K
462.5K – 462.5K
|
—
— – —
-100.0% YoY
|
80.43M
80.43M – 80.43M
|
137.95M
137.95M – 137.95M
+71.5% YoY
|
406.30M
406.30M – 406.30M
+194.5% YoY
|
| EBITDA |
-31.58M
est: 15.00M (-310.5%)
|
-71.89M
est: 543.0K (-13,338.5%)
|
-103.33M
|
277.5K
277.5K – 277.5K
|
—
— – —
-100.0% YoY
|
48.26M
48.26M – 48.26M
|
82.77M
82.77M – 82.77M
+71.5% YoY
|
243.78M
243.78M – 243.78M
+194.5% YoY
|
| EBIT |
-31.58M
est: 15.00M (-310.5%)
|
-75.13M
est: 543.0K (-13,936.5%)
|
-103.21M
|
277.5K
277.5K – 277.5K
|
—
— – —
-100.0% YoY
|
48.26M
48.26M – 48.26M
|
82.77M
82.77M – 82.77M
+71.5% YoY
|
243.78M
243.78M – 243.78M
+194.5% YoY
|
| Net Income |
-31.59M
est: -470.80M (+93.3%)
|
-75.14M
est: -80.87M (+7.1%)
|
-90.35M
est: -90.35M (+0.0%)
|
-118.60M
-149.84M – -85.39M
-31.3% YoY
|
-127.70M
-131.77M – -94.98M
-7.7% YoY
|
-83.32M
-180.56M – 14.52M
+34.8% YoY
|
-30.22M
-30.22M – -30.22M
+63.7% YoY
|
144.65M
144.65M – 144.65M
+578.7% YoY
|
| SGA |
15.74M
est: 142.23M (-88.9%)
|
22.61M
est: 5.15M (+339.2%)
|
25.13M
|
2.63M
2.63M – 2.63M
|
—
— – —
-100.0% YoY
|
457.61M
457.61M – 457.61M
|
784.85M
784.85M – 784.85M
+71.5% YoY
|
2.31B
2.31B – 2.31B
+194.5% YoY
|
| EPS |
-1.34
est: -26.80 (+95.0%)
|
-4.28
est: -4.26 (-0.5%)
|
-4.24
est: -4.32 (+1.9%)
|
-5.19
-7.08 – -4.03
-20.1% YoY
|
-5.42
-6.22 – -4.49
-4.4% YoY
|
-4.24
-8.53 – 0.69
+21.7% YoY
|
-1.43
-1.43 – -1.43
+66.4% YoY
|
6.83
6.83 – 6.83
+578.7% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-324.59M
OE per share TTM
-15.72
Owner's Yield
-67.84%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
13,355.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
30
Total invested
36.15M
Insider transactions (90d)
3
Beneficial owners (>5%)
11
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 1.39M | 10.70% | 1.39M | — | 1.39M | — | HC | Delaware | 2024-07-08 | ↗ |
| 2 | RTW Investments, LP | 1.14M | 8.70% | — | 1.14M | — | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 3 | Roderick Wong, M.D. | 1.14M | 8.70% | — | 1.14M | — | — | HC, IN | Delaware | 2024-11-14 | ↗ |
| 4 | Casdin Capital, LLC | 1.02M | 6.90% | — | 1.02M | — | 1.02M | IA | Delaware | 2024-11-08 | ↗ |
| 5 | Eli Casdin | 1.02M | 6.90% | — | 1.02M | — | 1.02M | HC, IN | Delaware | 2024-11-08 | ↗ |
| 6 | Casdin Partners GP, LLC | 804.3K | 5.40% | — | 804.3K | — | 804.3K | OO | Delaware | 2024-11-08 | ↗ |
| 7 | Casdin Partners Master Fund, L.P. | 804.3K | 5.40% | — | 804.3K | — | 804.3K | PN | Delaware | 2024-11-08 | ↗ |
| 8 | Capital LP | 800.0K | 5.40% | — | 800.0K | — | 800.0K | IA | Delaware, USA | 2024-12-11 | ↗ |
| 9 | Capital Master LP | 800.0K | 5.40% | — | 800.0K | — | 800.0K | OO | Delaware, USA | 2024-12-11 | ↗ |
| 10 | Abigail P. Johnson | 731.8K | 5.63% | — | — | 731.8K | — | IN | Delaware | 2024-11-12 | ↗ |
| 11 | FMR LLC | 731.8K | 5.63% | 731.8K | — | 731.8K | — | HC | Delaware | 2024-11-12 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
30
-64 vs prev Q
New positions
7
Closed positions
71
Increased
23
Reduced
5
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 785.0K +785.0K (+100.0%) | 16.17B +16.2B (+100.0%) | 3.71% +3.708 pp | 4.00% +3.995 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 2 | SAMSARA BIOCAPITAL, LLC | 1.72M +— (+0.0%) | 35.37M +5.6M (+18.9%) | 8.11% -0.044 pp | 3.65% -0.236 pp | USD20.29 +1.5% | 9 qtrs — |
| 3 | REDMILE GROUP, LLC | 1.46M +160.6K (+12.4%) | 30.07M +7.6M (+33.6%) | 6.90% +0.726 pp | 2.21% +0.024 pp | USD21.35 -3.5% | 9 qtrs — |
| 4 | RTW INVESTMENTS, LP | 1.36M +— (+0.0%) | 28.07M +4.5M (+18.9%) | 6.44% -0.035 pp | 0.28% -0.010 pp | USD41.10 -49.9% | 8 qtrs — |
| 5 | CASDIN CAPITAL, LLC | 1.30M +— (+0.0%) | 26.68M +4.2M (+18.9%) | 6.12% -0.033 pp | 1.66% -0.214 pp | USD21.45 -4.0% | 9 qtrs — |
| 6 | ECOR1 CAPITAL, LLC | 1.27M +— (+0.0%) | 26.19M +4.2M (+18.9%) | 6.01% -0.032 pp | 1.19% +0.131 pp | USD19.38 +6.3% | 9 qtrs — |
| 7 | BAKER BROS. ADVISORS LP | 991.7K +— (+0.0%) | 20.43M +3.2M (+18.9%) | 4.68% -0.025 pp | 0.12% -0.005 pp | USD15.75 +30.8% | 9 qtrs — |
| 8 | BLACKROCK, INC. | 945.6K -5.5K (-0.6%) | 19.48M +3.0M (+18.2%) | 4.47% -0.050 pp | 0.00% +0.000 pp | USD40.14 -48.7% | 6 qtrs — |
| 9 | TORONTO DOMINION BANK | 681.3K +— (+0.0%) | 14.04M +2.2M (+18.9%) | 3.22% -0.017 pp | 0.02% +0.002 pp | USD13.81 +49.2% | 4 qtrs — |
| 10 | VANGUARD GROUP INC | 656.6K +52.0K (+8.6%) | 13.53M +3.0M (+29.1%) | 3.10% +0.230 pp | 0.00% +0.000 pp | USD39.47 -47.8% | 9 qtrs — |
| 11 | BALYASNY ASSET MANAGEMENT L.P. | 608.6K -90.4K (-12.9%) | 12.54M +423.0K (+3.5%) | 2.87% -0.445 pp | 0.02% +0.001 pp | USD17.33 +18.9% | 2 qtrs — |
| 12 | ARROWMARK COLORADO HOLDINGS LLC | 577.5K -18.3K (-3.1%) | 11.90M +1.6M (+15.2%) | 2.73% -0.102 pp | 0.26% +0.070 pp | USD18.63 +10.6% | 9 qtrs — |
| 13 | JENNISON ASSOCIATES LLC | 533.1K +139.0K (+35.3%) | 10.98M +4.2M (+60.8%) | 2.52% +0.647 pp | 0.01% +0.003 pp | USD20.90 -1.4% | 6 qtrs — |
| 14 | MORGAN STANLEY | 371.2K -55.4K (-13.0%) | 7.65M +253.6K (+3.4%) | 1.75% -0.273 pp | 0.00% +0.000 pp | USD22.19 -7.2% | 9 qtrs — |
| 15 | CITADEL ADVISORS LLC | 364.2K +364.2K (+100.0%) | 7.50M +7.5M (+100.0%) | 1.72% +1.721 pp | 0.00% +0.001 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 16 | GREAT POINT PARTNERS LLC | 350.0K -96.8K (-21.7%) | 7.21M -533.3K (-6.9%) | 1.65% -0.469 pp | 2.34% -0.855 pp | USD19.05 +8.1% | 9 qtrs — |
| 17 | STATE STREET CORP | 307.8K +99.5K (+47.8%) | 6.34M +2.7M (+75.6%) | 1.45% +0.465 pp | 0.00% +0.000 pp | USD34.36 -40.0% | 8 qtrs — |
| 18 | GEODE CAPITAL MANAGEMENT, LLC | 249.7K +3.3K (+1.3%) | 5.14M +873.1K (+20.4%) | 1.18% +0.009 pp | 0.00% +0.000 pp | USD37.37 -44.9% | 9 qtrs — |
| 19 | LOGOS GLOBAL MANAGEMENT LP | 195.0K +195.0K (+100.0%) | 4.02M +4.0M (+100.0%) | 0.92% +0.921 pp | 0.24% +0.243 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 20 | BLAIR WILLIAM & CO/IL | 163.7K +21.8K (+15.4%) | 3.37M +913.6K (+37.2%) | 0.77% +0.100 pp | 0.01% +0.003 pp | USD16.95 +21.5% | 5 qtrs — |
| 21 | GOLDMAN SACHS GROUP INC | 162.0K +89.2K (+122.5%) | 3.34M +2.1M (+164.5%) | 0.77% +0.420 pp | 0.00% +0.000 pp | USD21.92 -6.0% | 8 qtrs — |
| 22 | UBS GROUP AG | 154.1K -73.6K (-32.3%) | 3.17M -771.4K (-19.5%) | 0.73% -0.353 pp | 0.00% 0.000 pp | USD22.08 -6.7% | 9 qtrs — |
| 23 | FMR LLC | 130.3K +14.8K (+12.8%) | 2.68M +682.3K (+34.1%) | 0.62% +0.067 pp | 0.00% +0.000 pp | USD36.65 -43.8% | 7 qtrs — |
| 24 | ROCK SPRINGS CAPITAL MANAGEMENT LP | 104.3K +— (+0.0%) | 2.15M +341.2K (+18.9%) | 0.49% -0.003 pp | 0.11% +0.005 pp | USD21.91 -6.0% | 5 qtrs — |
| 25 | DEUTSCHE BANK AG\ | 85.6K -66.7K (-43.8%) | 1.76M -876.3K (-33.2%) | 0.40% -0.319 pp | 0.00% 0.000 pp | USD42.00 -51.0% | 8 qtrs — |
| 26 | NORTHERN TRUST CORP | 85.6K -4.5K (-5.0%) | 1.76M +201.1K (+12.9%) | 0.40% -0.024 pp | 0.00% +0.000 pp | USD39.17 -47.4% | 8 qtrs — |
| 27 | WOODLINE PARTNERS LP | 83.8K +— (+0.0%) | 1.73M +274.1K (+18.9%) | 0.40% -0.002 pp | 0.01% 0.000 pp | USD41.74 -50.6% | 6 qtrs — |
| 28 | MILLENNIUM MANAGEMENT LLC | 71.3K -176.5K (-71.2%) | 1.47M -2.8M (-65.8%) | 0.34% -0.840 pp | 0.00% -0.001 pp | USD13.29 +55.0% | 8 qtrs — |
| 29 | SCHRODER INVESTMENT MANAGEMENT GROUP | 52.3K +22.1K (+73.3%) | 1.16M +621.9K (+116.4%) | 0.25% +0.104 pp | 0.00% +0.001 pp | USD17.34 +18.8% | 3 qtrs — |
| 30 | RAIFFEISEN BANK INTERNATIONAL AG | 42.0K +8.0K (+23.5%) | 928.6K +326.5K (+54.2%) | 0.20% +0.037 pp | 0.01% +0.004 pp | USD18.19 +13.2% | 5 qtrs — |
| 31 | TREXQUANT INVESTMENT LP | 43.3K +3.8K (+9.7%) | 892.5K +208.2K (+30.4%) | 0.20% +0.017 pp | 0.01% +0.001 pp | USD17.62 +16.9% | 2 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 41.8K +1.2K (+3.0%) | 860.2K +157.5K (+22.4%) | 0.20% +0.005 pp | 0.00% +0.000 pp | USD18.41 +11.9% | 9 qtrs — |
| 33 | D. E. SHAW & CO., INC. | 40.3K +40.3K (+100.0%) | 831.1K +831.1K (+100.0%) | 0.19% +0.191 pp | 0.00% +0.001 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 34 | WALLEYE CAPITAL LLC | 36.1K +36.1K (+100.0%) | 743.7K +743.7K (+100.0%) | 0.17% +0.171 pp | 0.00% +0.002 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 35 | DRIEHAUS CAPITAL MANAGEMENT LLC | 32.8K +— (+0.0%) | 675.0K +107.1K (+18.9%) | 0.15% -0.001 pp | 0.00% +0.001 pp | USD43.37 -52.5% | 8 qtrs — |
| 36 | SQUAREPOINT OPS LLC | 32.5K +32.5K (+100.0%) | 669.3K +669.3K (+100.0%) | 0.15% +0.154 pp | 0.00% +0.001 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 37 | ADAR1 CAPITAL MANAGEMENT, LLC | 30.6K +— (+0.0%) | 631.0K +100.2K (+18.9%) | 0.14% -0.001 pp | 0.05% -0.004 pp | USD12.07 +70.7% | 9 qtrs — |
| 38 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 30.0K +— (+0.0%) | 617.2K +98.0K (+18.9%) | 0.14% -0.001 pp | 0.00% +0.000 pp | USD38.49 -46.5% | 8 qtrs — |
| 39 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 29.1K -3.4K (-10.5%) | 599.9K +36.3K (+6.4%) | 0.14% -0.017 pp | 0.00% -0.001 pp | USD17.33 +18.9% | 2 qtrs — |
| 40 | DAFNA CAPITAL MANAGEMENT LLC | 28.0K -2.4K (-7.9%) | 576.3K +49.9K (+9.5%) | 0.13% -0.012 pp | 0.13% +0.004 pp | USD25.54 -19.3% | 7 qtrs — |
| 41 | SCHONFELD STRATEGIC ADVISORS LLC | 27.9K +27.9K (+100.0%) | 574.6K +574.6K (+100.0%) | 0.13% +0.132 pp | 0.00% +0.003 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 42 | LOS ANGELES CAPITAL MANAGEMENT LLC | 14.5K +14.5K (+100.0%) | 481.5K +481.5K (+100.0%) | 0.07% +0.069 pp | 0.00% +0.002 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 43 | BANK OF NEW YORK MELLON CORP | 23.1K -1.6K (-6.3%) | 475.7K +48.5K (+11.4%) | 0.11% -0.008 pp | 0.00% +0.000 pp | USD37.68 -45.3% | 7 qtrs — |
| 44 | NUVEEN, LLC | 21.1K +— (+0.0%) | 434.5K +69.0K (+18.9%) | 0.10% -0.001 pp | 0.00% +0.000 pp | USD11.71 +75.9% | 4 qtrs — |
| 45 | AMERICAN CENTURY COMPANIES INC | 17.6K +3.9K (+28.8%) | 361.7K +125.5K (+53.1%) | 0.08% +0.018 pp | 0.00% +0.000 pp | USD18.06 +14.1% | 2 qtrs — |
| 46 | BARCLAYS PLC | 15.4K +516.0 (+3.5%) | 316.7K -306.8K (-49.2%) | 0.07% +0.002 pp | 0.00% 0.000 pp | USD34.28 -39.9% | 8 qtrs — |
| 47 | JANE STREET GROUP, LLC | 15.1K -47.3K (-75.8%) | 311.2K -770.4K (-71.2%) | 0.07% -0.225 pp | 0.00% 0.000 pp | USD17.33 +18.9% | 2 qtrs — |
| 48 | RENAISSANCE TECHNOLOGIES LLC | 14.0K +14.0K (+100.0%) | 288.4K +288.4K (+100.0%) | 0.07% +0.066 pp | 0.00% +0.000 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 49 | RHUMBLINE ADVISERS | 13.4K -1.7K (-11.1%) | 275.7K +14.7K (+5.6%) | 0.06% -0.008 pp | 0.00% +0.000 pp | USD39.20 -47.4% | 7 qtrs — |
| 50 | ALPS ADVISORS INC | 12.7K +12.7K (+100.0%) | 262.1K +262.1K (+100.0%) | 0.06% +0.060 pp | 0.00% +0.002 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 51 | VIRTUS INVESTMENT ADVISERS, INC. | 12.7K +7.1K (+128.0%) | 262.0K +165.3K (+171.0%) | 0.06% +0.034 pp | 0.07% +0.044 pp | USD17.13 +20.3% | 4 qtrs — |
| 52 | TWO SIGMA INVESTMENTS, LP | 12.0K -8.6K (-41.7%) | 247.0K -109.1K (-30.6%) | 0.06% -0.041 pp | 0.00% 0.000 pp | USD19.13 +7.7% | 5 qtrs — |
| 53 | DIMENSIONAL FUND ADVISORS LP | 11.4K +11.4K (+100.0%) | 235.0K +235.0K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 54 | WELLS FARGO & COMPANY/MN | 11.0K +3.4K (+45.2%) | 227.4K +95.7K (+72.6%) | 0.05% +0.016 pp | 0.00% +0.000 pp | USD26.26 -21.6% | 9 qtrs — |
| 55 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 10.8K +— (+0.0%) | 222.1K +35.3K (+18.9%) | 0.05% 0.000 pp | 0.00% +0.001 pp | USD17.33 +18.9% | 2 qtrs — |
| 56 | ALLIANCEBERNSTEIN L.P. | 10.6K +— (+0.0%) | 217.7K +34.6K (+18.9%) | 0.05% 0.000 pp | 0.00% +0.000 pp | USD14.95 +37.8% | 3 qtrs — |
| 57 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 10.0K -13.3K (-57.1%) | 206.0K -197.8K (-49.0%) | 0.05% -0.063 pp | 0.00% +0.000 pp | USD15.70 +31.2% | 5 qtrs — |
| 58 | MITSUBISHI UFJ KOKUSAI ASSET MANAGEMENT CO., LTD. | 8.2K +8.2K (+100.0%) | 165.2K +165.2K (+100.0%) | 0.04% +0.039 pp | 0.00% +0.000 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 59 | QUEST PARTNERS LLC | 7.2K -9.2K (-56.2%) | 148.6K -136.5K (-47.9%) | 0.03% -0.044 pp | 0.01% -0.010 pp | USD15.58 +32.2% | 7 qtrs — |
| 60 | METLIFE INVESTMENT MANAGEMENT, LLC | 5.9K +— (+0.0%) | 122.2K +19.4K (+18.9%) | 0.03% 0.000 pp | 0.00% +0.000 pp | USD41.96 -50.9% | 6 qtrs — |
| 61 | JPMORGAN CHASE & CO | 5.4K -200.0 (-3.6%) | 110.5K +14.1K (+14.6%) | 0.03% -0.001 pp | 0.00% +0.000 pp | USD23.03 -10.6% | 9 qtrs — |
| 62 | PNC FINANCIAL SERVICES GROUP, INC. | 5.1K +69.0 (+1.4%) | 105.6K +18.0K (+20.5%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD19.85 +3.8% | 5 qtrs — |
| 63 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 4.6K -34.0 (-0.7%) | 94.6K +14.4K (+18.0%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD36.75 -43.9% | 6 qtrs — |
| 64 | NEW YORK STATE COMMON RETIREMENT FUND | 4.2K +— (+0.0%) | 86.5K +13.7K (+18.9%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD40.62 -49.3% | 7 qtrs — |
| 65 | DAIWA SECURITIES GROUP INC. | 3.2K +3.2K (+100.0%) | 66.0K +66.0K (+100.0%) | 0.02% +0.015 pp | 0.00% +0.000 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 66 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 2.5K +22.0 (+0.9%) | 52.0K +8.6K (+19.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD22.84 -9.8% | 5 qtrs — |
| 67 | BNP PARIBAS ARBITRAGE, SNC | 2.4K +357.0 (+17.3%) | 49.9K +14.1K (+39.4%) | 0.01% +0.002 pp | 0.00% +0.000 pp | USD25.82 -20.2% | 7 qtrs — |
| 68 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 2.0K -1.1K (-35.9%) | 41.5K -13.0K (-23.8%) | 0.01% -0.005 pp | 0.00% 0.000 pp | USD20.98 -1.8% | 5 qtrs — |
| 69 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.2K +66.0 (+5.7%) | 25.4K +5.2K (+25.6%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD23.58 -12.6% | 6 qtrs — |
| 70 | AMERITAS INVESTMENT PARTNERS, INC. | 1.0K +— (+0.0%) | 20.8K +3.3K (+18.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD40.62 -49.3% | 7 qtrs — |
| 71 | LEGAL & GENERAL GROUP PLC | 898.00 +— (+0.0%) | 18.5K +2.9K (+18.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD35.73 -42.3% | 7 qtrs — |
| 72 | RUSSELL INVESTMENTS GROUP, LTD. | 856.00 +— (+0.0%) | 17.6K +2.8K (+18.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD17.21 +19.7% | 3 qtrs — |
| 73 | CITIGROUP INC | 754.00 +365.0 (+93.8%) | 15.5K +8.8K (+130.4%) | 0.00% +0.002 pp | 0.00% +0.000 pp | USD30.68 -32.9% | 8 qtrs — |
| 74 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 753.00 +201.0 (+36.4%) | 15.5K +5.9K (+62.2%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD21.62 -4.7% | 5 qtrs — |
| 75 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 606.00 -11.0 (-1.8%) | 12.5K +1.8K (+16.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD40.62 -49.3% | 7 qtrs — |
| 76 | STERLING CAPITAL MANAGEMENT LLC | 567.00 -112.0 (-16.5%) | 11.7K -87.0 (-0.7%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD17.97 +14.6% | 6 qtrs — |
| 77 | ROYAL BANK OF CANADA | 430.00 +19.0 (+4.6%) | 9.0K +2.0K (+28.6%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD26.65 -22.7% | 9 qtrs — |
| 78 | GAMMA INVESTING LLC | 408.00 -109.0 (-21.1%) | 8.4K -555.0 (-6.2%) | 0.00% -0.001 pp | 0.00% 0.000 pp | USD16.51 +24.8% | 5 qtrs — |
| 79 | GF FUND MANAGEMENT CO. LTD. | 302.00 -14.0 (-4.4%) | 6.2K +745.0 (+13.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD21.16 -2.6% | 5 qtrs — |
| 80 | AMALGAMATED BANK | 309.00 -47.0 (-13.2%) | 6.0K +— (+0.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD40.61 -49.3% | 7 qtrs — |
| 81 | US BANCORP \DE\ | 163.00 +152.0 (+1,381.8%) | 3.4K +3.2K (+1,658.1%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD21.94 -6.1% | 9 qtrs — |
| 82 | CWM, LLC | 154.00 -20.0 (-11.5%) | 3.0K +— (+0.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD15.25 +35.1% | 3 qtrs — |
| 83 | SIMPLEX TRADING, LLC | 62.00 -1.2K (-95.0%) | 1.3K -19.7K (-93.9%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD13.34 +54.4% | 4 qtrs — |
| 84 | OPTIVER HOLDING B.V. | 61.00 -15.0 (-19.7%) | 1.3K -60.0 (-4.6%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD17.33 +18.9% | 2 qtrs — |
| 85 | TRUVESTMENTS CAPITAL LLC | 46.00 +— (+0.0%) | 948.00 +151.0 (+18.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD41.96 -50.9% | 9 qtrs — |
| 86 | NISA INVESTMENT ADVISORS, LLC | 45.00 +— (+0.0%) | 927.00 +147.0 (+18.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.69 +76.2% | 6 qtrs — |
| 87 | SAGEVIEW ADVISORY GROUP, LLC | 45.00 +45.0 (+100.0%) | 927.00 +927.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD20.60 +0.0% | 1 qtrs NEW |
| 88 | EVERSOURCE WEALTH ADVISORS, LLC | 44.00 +— (+0.0%) | 907.00 +145.0 (+19.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD15.11 +36.3% | 4 qtrs — |
| 89 | ROTHSCHILD INVESTMENT LLC | 40.00 +— (+0.0%) | 824.00 +131.0 (+18.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.93 +38.0% | 3 qtrs — |
| 90 | VERSANT CAPITAL MANAGEMENT, INC | 33.00 +— (+0.0%) | 680.00 +108.0 (+18.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD14.94 +37.9% | 3 qtrs — |
| 91 | SBI SECURITIES CO., LTD. | 25.00 -2.0 (-7.4%) | 515.00 +47.0 (+10.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD19.44 +6.0% | 5 qtrs — |
| 92 | NATIONAL BANK OF CANADA /FI/ | 8.00 +— (+0.0%) | 164.00 +25.0 (+18.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD11.63 +77.1% | 9 qtrs — |
| 93 | SRS CAPITAL ADVISORS, INC. | 2.00 -14.0 (-87.5%) | 41.00 -236.0 (-85.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD17.00 +21.2% | 2 qtrs — |
| 94 | FARTHER FINANCE ADVISORS, LLC | — -597.0 (-100.0%) | — -10.3K (-100.0%) | 0.00% -0.003 pp | 0.00% 0.000 pp | USD— | 9 qtrs SOLD |
| 95 | POINT72 ASSET MANAGEMENT, L.P. | — -7.7K (-100.0%) | — -132.9K (-100.0%) | 0.00% -0.036 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 96 | QUADRATURE CAPITAL LTD | — -16.8K (-100.0%) | — -292.0K (-100.0%) | 0.00% -0.080 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 97 | BREVAN HOWARD CAPITAL MANAGEMENT LP | — -12.9K (-100.0%) | — -223.2K (-100.0%) | 0.00% -0.061 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 98 | BESSEMER GROUP INC | — -87.0 (-100.0%) | — -2.0K (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 99 | XTX TOPCO LTD | — -12.0K (-100.0%) | — -208.0K (-100.0%) | 0.00% -0.057 pp | 0.00% -0.011 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 61 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.84% | 482.5K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.32% | 683.8K | 0.50% |
| 3 | Franklin Genomic Advancements ETF HELX | 0.28% | 84.1K | 0.50% |
| 4 | Xtrackers S&P 500 2x Leveraged Daily Swap UCITS ETF 1C XS2D.L | 0.13% | 820.0K | 0.60% |
| 5 | iShares Micro-Cap ETF IWC | 0.10% | 1.49M | 0.60% |
| 6 | Fidelity Enhanced Small Cap ETF FESM | 0.06% | 3.64M | 0.28% |
| 7 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.04% | 199.5K | 0.40% |
| 8 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.04% | 32.1K | 0.19% |
| 9 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.04% | 29.1K | 0.35% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.04% | 435.3K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.50
Neutral
Ratio by volume
3.00
Bullish
Buys
1
Sells
2
Shares acquired
120.0K
Shares disposed
9.6K
Cash buys
—
Cash sales
2.00
Net activity
+110,400
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Cvijic Christine Mikail | Director / Officer | S-Sale | D | Common Stock | 4,800 | 30.07 | 144.4K | 98,440 | D | ↗ |
| 2026-05-05 | Shafer Christina | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 120,000 | 28.94 | 3.47M | 120,000 | D | ↗ |
| 2026-04-20 | Shafer Christina | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-26 | McMinn Rachel | Director / Officer | S-Sale | D | Common Stock | 3,352 | 22.07 | 74.0K | 1,344,307 | D | ↗ |
| 2026-03-26 | Jordan Julie | Officer | S-Sale | D | Common Stock | 828 | 21.89 | 18.1K | 12,472 | D | ↗ |
| 2026-03-26 | Cvijic Christine Mikail | Officer | S-Sale | D | Common Stock | 2,558 | 21.62 | 55.3K | 103,240 | D | ↗ |
| 2026-03-13 | Cvijic Christine Mikail | Officer | S-Sale | D | Common Stock | 2,387 | 20.42 | 48.7K | 107,456 | D | ↗ |
| 2026-03-13 | Cobb Stuart | Officer | S-Sale | D | Common Stock | 148 | 22.08 | 3.3K | 30,497 | D | ↗ |
| 2026-02-27 | Cvijic Christine Mikail | Officer | S-Sale | D | Common Stock | 4,800 | 25.11 | 120.5K | 109,843 | D | ↗ |
| 2026-02-20 | Woods Keith | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 17.64 | 212.6K | 12,050 | D | ↗ |
| 2026-02-20 | PALEKAR ROHAN | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 17.64 | 212.6K | 12,050 | D | ↗ |
| 2026-02-20 | Noonberg Sarah B. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 17.64 | 212.6K | 12,050 | D | ↗ |
| 2026-02-20 | McMinn Rachel | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 155,100 | 17.64 | 2.74M | 155,100 | D | ↗ |
| 2026-02-20 | Jordan Julie | Officer | A-Award | A | Stock Option (Right to Buy) | 29,600 | 17.64 | 522.1K | 29,600 | D | ↗ |
| 2026-02-20 | Freedland Cory S. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 17.64 | 212.6K | 12,050 | D | ↗ |
| 2026-02-20 | Cvijic Christine Mikail | Officer | A-Award | A | Common Stock | 22,000 | 0.00 | — | 114,643 | D | ↗ |
| 2026-02-20 | Cobb Stuart | Officer | A-Award | A | Common Stock | 16,500 | 0.00 | — | 37,294 | D | ↗ |
| 2026-02-20 | BAFFI ROBERT | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 17.64 | 212.6K | 12,050 | D | ↗ |
| 2025-06-12 | Woods Robert Keith | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 20.40 | 245.8K | 12,050 | D | ↗ |
| 2025-06-12 | PALEKAR ROHAN | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 20.40 | 245.8K | 12,050 | D | ↗ |
| 2025-06-12 | Noonberg Sarah B. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 20.40 | 245.8K | 12,050 | D | ↗ |
| 2025-06-12 | Freedland Cory S. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 20.40 | 245.8K | 12,050 | D | ↗ |
| 2025-06-12 | BAFFI ROBERT | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,050 | 20.40 | 245.8K | 12,050 | D | ↗ |
| 2025-05-14 | Cobb Stuart | Officer | S-Sale | D | Common Stock | 6,797 | 15.15 | 103.0K | 20,794 | D | ↗ |
| 2025-03-26 | McMinn Rachel | Director / Officer | A-Award | A | Common Stock | 23,900 | 0.00 | — | 1,274,259 | D | ↗ |
| 2025-03-26 | Jordan Julie | Officer | A-Award | A | Employee Stock Option (Right to buy) | 50,300 | 16.14 | 811.8K | 50,300 | D | ↗ |
| 2025-03-26 | Cvijic Christine Mikail | Officer | A-Award | A | Common Stock | 20,300 | 0.00 | — | 92,643 | D | ↗ |
| 2025-03-26 | Cobb Stuart | Officer | A-Award | A | Employee Stock Option (Right to buy) | 42,900 | 16.14 | 692.4K | 42,900 | D | ↗ |
| 2025-03-13 | Cvijic Christine Mikail | Officer | S-Sale | D | Common Stock | 4,501 | 16.94 | 76.2K | 72,343 | D | ↗ |
| 2024-11-26 | Samsara BioCapital GP, LLC | 10% Owner | P-Purchase | A | Common Stock | 15,219 | 26.73 | 406.8K | 1,715,127 | I | ↗ |
| 2024-11-25 | Samsara BioCapital GP, LLC | 10% Owner | — | — | Pre-Funded Warrants (Right to Buy) | 20,000 | 0.00 | 20.00 | 0 | I | ↗ |
| 2024-11-22 | McMinn Rachel | Director / Officer | P-Purchase | A | Common Stock | 47,500 | 20.40 | 969.0K | 1,297,859 | D | ↗ |
| 2024-11-22 | Cvijic Christine Mikail | Officer | P-Purchase | A | Common Stock | 24,000 | 20.48 | 491.4K | 76,844 | D | ↗ |
| 2024-06-14 | Woods Robert Keith | Director | A-Award | A | Stock Option (Right to Buy) | 7,700 | 42.59 | 327.9K | 7,700 | — | ↗ |
| 2024-06-14 | PALEKAR ROHAN | Director | A-Award | A | Stock Option (Right to Buy) | 7,700 | 42.59 | 327.9K | 7,700 | — | ↗ |
| 2024-06-14 | Noonberg Sarah B. | Director | A-Award | A | Stock Option (Right to Buy) | 7,700 | 42.59 | 327.9K | 7,700 | — | ↗ |
| 2024-06-14 | Freedland Cory S. | Director | A-Award | A | Stock Option (Right to Buy) | 7,700 | 42.59 | 327.9K | 7,700 | — | ↗ |
| 2024-06-14 | BAFFI ROBERT | Director | A-Award | A | Stock Option (Right to Buy) | 7,700 | 42.59 | 327.9K | 7,700 | — | ↗ |
| 2024-03-13 | McMinn Rachel | Director / Officer | A-Award | A | Employee Stock Option (Right to buy) | 93,282 | 36.06 | 3.36M | 93,282 | — | ↗ |
| 2024-03-13 | Cvijic Christine Mikail | Officer | A-Award | A | Employee Stock Option (Right to buy) | 53,900 | 36.06 | 1.94M | 53,900 | — | ↗ |
| 2024-03-13 | Cobb Stuart | Officer | A-Award | A | Stock Option (Right to Buy) | 34,450 | 36.06 | 1.24M | 34,450 | — | ↗ |
| 2023-12-18 | BAKER BROS. ADVISORS LP | Director / 10% Owner | A-Award | A | Prefunded Warrants | 973,290 | 0.00 | — | 973,290 | — | ↗ |
Executive team
Top executives
Shares Outstanding
15.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Donna Cochener Former Interim Chief Executive Officer and General Counsel | 423.6K | 219.4K | — | — | 264.9K | 919.5K | 1.83M | 0.00% | ↗ |
| 2 | 2023 | Sean Smith Former Interim Chief Financial Officer | 384.1K | 159.2K | — | — | 192.2K | 1.07M | 1.81M | 0.00% | ↗ |
| 3 | 2023 | Christine Mikail President and Chief Financial Officer | 455.8K | 167.5K | — | 509.2K | — | — | 1.13M | 44.96% | ↗ |
| 4 | 2023 | Rachel McMinn Founder and Chief Executive Officer | 467.9K | 196.5K | — | 404.1K | — | 12.1K | 1.08M | 37.39% | ↗ |
| 5 | 2023 | Stuart Cobb Chief Scientific Officer | 362.3K | 116.5K | — | 305.5K | — | — | 784.3K | 38.95% | ↗ |
| 6 | 2023 | Jonathan Drachman Former Chief Executive Officer and President | 113.5K | — | — | — | — | 436.4K | 550.0K | 0.00% | ↗ |
| 7 | 2022 | Donna Cochener Former Interim Chief Executive Officer and General Counsel | 291.0K | — | — | 590.1K | 108.2K | 4.5K | 993.9K | 59.38% | ↗ |
| 8 | 2022 | Jonathan Drachman Former Chief Executive Officer and President | 453.0K | — | — | 251.7K | 192.5K | 5.0K | 902.2K | 27.89% | ↗ |
| 9 | 2022 | Rachel McMinn Founder and Chief Executive Officer | 447.7K | 206.0K | — | — | — | 2.8K | 656.5K | 0.00% | ↗ |
| 10 | 2022 | Christine Mikail President and Chief Financial Officer | 436.2K | 175.6K | — | — | — | — | 611.7K | 0.00% | ↗ |
| 11 | 2022 | Stuart Cobb Chief Scientific Officer | 341.3K | 117.7K | — | — | — | — | 459.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Rachel L. McMinn | Founder, Executive Chair & Chief Executive Officer | 997.2K | — |
| Christine Mikail Cvijic | President, CFO & Director | 874.1K | female |
| Julie Jordan | Chief Medical Officer | 696.3K | — |
| Stuart Cobb | Chief Scientific Officer | 478.8K | — |
| Ricardo Jimenez | Senior Vice President of Technical Operations | — | male |
| Donna Cochener-Metcalfe | Senior Vice President, General Counsel & Corporate Secretary | — | female |
| Arvind Sreedharan | Senior Vice President of Business Operations | — | male |
| Christina Shafer | Chief Commercial Officer | — | female |
| Andrew E. Mulberg FAAP | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for NGNE
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
